PMID- 37583693
OWN - NLM
STAT- MEDLINE
DCOM- 20230817
LR  - 20230817
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Transarterial chemoembolization combined with molecularly targeted agents plus 
      immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a 
      retrospective cohort study.
PG  - 1205636
LID - 10.3389/fimmu.2023.1205636 [doi]
LID - 1205636
AB  - PURPOSE: To retrospectively evaluate and compare treatment effectiveness and 
      safety between transarterial chemoembolization (TACE) combined with molecularly 
      targeted agents plus immune checkpoint inhibitors (TACE+T+I) and TACE combined 
      with molecularly targeted agents (TACE+T) for unresectable hepatocellular 
      carcinoma (uHCC). METHODS: We retrospectively analyzed the data of patients with 
      unresectable HCC from January 2018 to June 2022. The patients were screened based 
      on the inclusion criteria and were divided into the triple combination group 
      (TACE+T+I) and the double combination group (TACE+T). The primary outcomes were 
      overall survival (OS), progression-free survival (PFS), and adverse events (AEs). 
      The secondary outcomes were objective response rate (ORR) and disease control 
      rate (DCR). Risk factors associated with PFS and OS were determined by Cox 
      regression analysis. RESULTS: A total of 87 patients were enrolled in this study, 
      including 42 patients in the TACE+T+I group and 45 patients in the TACE+T group. 
      Over a median follow-up of 29.00 and 26.70 months, patients who received TACE+T+I 
      therapy achieved a significantly longer median OS (24.00 vs. 21.40 months, p = 
      0.007) and median PFS (9.70 vs. 7.00 months, p = 0.017); no grade 4 AEs or 
      treatment-related death occurred in the two groups. Grade 3 AEs attributed to 
      systemic agents in the two groups showed no significant difference (19.0% vs. 
      15.6%, p = 0.667). Patients in the TACE+T+I group demonstrated better tumor 
      response when compared with patients in the TACE+T group, with an ORR of 52.4% 
      vs. 17.8% (p = 0.001). No significant difference was observed in DCR between the 
      two groups (83.3% vs. 77.8%, p = 0.514). Cox regression analysis showed that only 
      the treatment method was an independent factor of OS, and both age and treatment 
      method were independent factors related to PFS. CONCLUSION: Compared with TACE 
      plus molecularly targeted agents (TACE+T), the triple therapy (TACE+T+I) could 
      improve survival and tumor response in unresectable HCC with manageable 
      toxicities.
CI  - Copyright (c) 2023 Jiang, Zhong, Huang, Li, Zhang, Zhu, Ni and Shen.
FAU - Jiang, Nan
AU  - Jiang N
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
FAU - Zhong, Binyan
AU  - Zhong B
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
FAU - Huang, Jintao
AU  - Huang J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
FAU - Li, Wanci
AU  - Li W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
FAU - Zhang, Shuai
AU  - Zhang S
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
FAU - Zhu, Xiaoli
AU  - Zhu X
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
FAU - Ni, Caifang
AU  - Ni C
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
FAU - Shen, Jian
AU  - Shen J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20230731
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/therapy
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - *Liver Neoplasms/therapy
MH  - *Antineoplastic Agents
PMC - PMC10425157
OTO - NOTNLM
OT  - combination therapy
OT  - immune therapy
OT  - targeted therapy
OT  - transarterial chemoembolization
OT  - unresectable hepatocellular carcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/16 06:43
MHDA- 2023/08/17 06:43
PMCR- 2023/01/01
CRDT- 2023/08/16 03:50
PHST- 2023/04/14 00:00 [received]
PHST- 2023/07/11 00:00 [accepted]
PHST- 2023/08/17 06:43 [medline]
PHST- 2023/08/16 06:43 [pubmed]
PHST- 2023/08/16 03:50 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1205636 [doi]
PST - epublish
SO  - Front Immunol. 2023 Jul 31;14:1205636. doi: 10.3389/fimmu.2023.1205636. 
      eCollection 2023.